Trevi Therapeutics, Inc. (TRVI)

Trevi Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	12.15	10.24	10.07	9.49	10.16
Research & Development	39.38	23.68	19.83	22.98	22.33
Operating Expenses	51.52	33.92	29.91	32.48	32.49
Operating Income	-51.52	-33.92	-29.91	-32.48	-32.49
Interest Expense	-0	-0.39	-1.16	-1.2	-0.46
Interest & Investment Income	3.6	4.75	1.74	0.01	0.18
Other Non Operating Income (Expenses)	-0.02	0.47	0.14	-0.29	-0.01
EBT Excluding Unusual Items	-47.94	-29.1	-29.19	-33.96	-32.78
Pretax Income	-47.94	-29.1	-29.19	-33.96	-32.78
Income Tax Expense	-0.03	-0.03	-0.04	-0.02	-0.02
Net Income	-47.91	-29.07	-29.15	-33.94	-32.76
Net Income to Common	-47.91	-29.07	-29.15	-33.94	-32.76
Shares Outstanding (Basic)	102	99	65	23	18
Shares Outstanding (Diluted)	102	99	65	23	18
Shares Change (YoY)	2.97%	53.44%	182.56%	26.48%	53.88%
EPS (Basic)	-0.47	-0.29	-0.45	-1.49	-1.81
EPS (Diluted)	-0.47	-0.29	-0.45	-1.49	-1.81
Free Cash Flow	-38.29	-31.85	-28.33	-28.95	-29.03
Free Cash Flow Per Share	-0.38	-0.32	-0.44	-1.27	-1.61
EBITDA	-51.38	-33.8	-29.86	-32.43	-32.44
D&A For EBITDA	0.15	0.12	0.04	0.05	0.05
EBIT	-51.52	-33.92	-29.91	-32.48	-32.49

Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q